NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of IB-Stim® , which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) ...

NeurAxis (NRXS) specializes in neuromodulation therapies, targeting chronic abdominal pain in pediatric and adult patients.

CARMEL, Ind., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

Shares of NeurAxis, Inc. NRXS have gained 41.2% since it reported earnings for the quarter ended Sept. 30, 2024. This strong performance contrasts with the S&P 500 index, which saw a decline of 0.9% ...

CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

Shares of NeurAxis, Inc. NRXS have lost 0.8% since the company reported its earnings for the quarter ended June 30, 2025. This compares unfavorably with the S&P 500 Index’s 1.2% gain during the same ...

The average one-year price target for NeurAxis (NYSEAM:NRXS) has been revised to $11.22 / share. This is an increase of 29.41% from the prior estimate of $8.67 dated April 12, 2026. The price target ...

CARMEL, Ind., Sept. 12, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that ...

Despite experiencing an operating loss, Neuraxis remains optimistic about its future growth, supported by new FDA indications and strategic initiatives. Additionally, Neuraxis entered into an At The ...

Neuraxis intends to raise $33.3 million in gross proceeds from an IPO of its common stock, although the final figure may vary. No existing shareholders have indicated an interest in purchasing shares ...